Presence of minority resistant variants after failure of a tenofovir, emtricitabine, and rilpivirine regimen

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 2, 2016, Pages e43-e45

  Todesco, Eve ^a,b,c   Surgers, Laure ^b   Marcelin, Anne Geneviève ^a,c   Calvez, Vincent ^a,c   Meynard, Jean Luc ^a   Morand Joubert, Laurence ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; RILPIVIRINE; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL RESISTANCE; CASE REPORT; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MUTATIONAL LOAD; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EMTRICITABINE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; RILPIVIRINE; RNA-DIRECTED DNA POLYMERASE; TENOFOVIR; VIRAL LOAD;

EID: 84955590314     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000935     Document Type: Letter

References (14)

1. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, et al; CHAIN Minority HIV-1 Variants Working Group. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015;70:930-940.
2. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency hiv-1 drug resistance mutations and risk of nnrti-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305: 1327-1335.
3. Li JZ, Paredes R, Ribaudo HJ, et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013;207:893-897.
4. Todesco E, Rodriguez C, Morand-Joubert L, et al. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. J Antimicrob Chemother. 2015;70:1503-1506.
5. Vandenhende MA, Bellecave P, Recordon-Pinson P, et al. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One. 2014; 9:e86771.
6. Surgers L, Valin N, Viala C, et al. Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients. J Acquir Immune Defic Syndr. 2015;68:e10-e12.
7. Daigle D, Simen BB, Pochart P. Highthroughput sequencing of PCR products tagged with universal primers using 454 life sciences systems. Curr Protoc Mol Biol. 2011; Chapter 7:Unit7.5.
8. Wang C, Mitsuya Y, Gharizadeh B, et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007; 17:1195-1201.
9. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90: 5653-5656.
10. Maserati R, De Silvestri A, Uglietti A, et al; ARCA Collaborative Group. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS. 2010;24: 1013-1018.
11. Fourati S, Malet I, Binka M, et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS. 2010;24: 2313-2321.
12. Fourati S, Lambert-Niclot S, Soulie C, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother. 2012;67:2323-2326.
13. Kim EY, Bhattacharya T, Kunstman K, et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol. 2010;84:10402-10405.
14. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2008; 105:5501-5506.